Comparative Analysis of Length of Stay, Total Costs, and Treatment Success between Intravenous Moxifloxacin 400 mg and Levofloxacin 750 mg among Hospitalized Patients with Community-Acquired Pneumonia

Nov 1, 2009, 00:00
10.1111/j.1524-4733.2009.00576.x
https://www.valueinhealthjournal.com/article/S1098-3015(10)60319-1/fulltext
Title : Comparative Analysis of Length of Stay, Total Costs, and Treatment Success between Intravenous Moxifloxacin 400 mg and Levofloxacin 750 mg among Hospitalized Patients with Community-Acquired Pneumonia
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)60319-1&doi=10.1111/j.1524-4733.2009.00576.x
First page :
Section Title :
Open access? : No
Section Order : 10

Objective

This study aimed to evaluate the length of stay (LOS), costs, and treatment consistency among patients hospitalized with community-acquired pneumonia (CAP) initially treated with intravenous (IV) moxifloxacin 400 mg or IV levofloxacin 750 mg.

Methods

Adults with CAP receiving IV moxifloxacin or IV levofloxacin for ≥3 days were identified in the Premier Perspective comparative database. Primary outcomes were LOS and costs. Secondary outcomes included treatment consistency, which was defined as 1) no additional IV moxifloxacin or levofloxacin after ≥1 day off study drug; 2) no switch to another IV antibiotic; and 3) no addition of another IV antibiotic.

Results

A total of 7720 patients met inclusion criteria (6040 receiving moxifloxacin; 1680 receiving levofloxacin). Propensity matching created two cohorts (1300 patients each) well matched for demographic, clinical, hospital, and payor characteristics. Before the patients were matched, mean LOS (5.87 vs. 5.46 days; P = 0.0004) and total costs per patient ($7302 vs. $6362; P P = 0.002).

Conclusions

In-hospital treatment of CAP with IV moxifloxacin 400 mg or IV levofloxacin 750 mg was associated with similar hospital LOS and costs in propensity-matched cohorts.

Categories :
  • Cost/Cost of Illness/Resource Use Studies
  • Cost-comparison, Effectiveness, Utility, Benefit Analysis
  • Economic Evaluation
  • Respiratory-Related Disorders
  • Retrospective Databases: Electronic Medical and Health Records, Admin Claims
  • Specific Diseases & Conditions
  • Study Approaches
Tags :
  • community-acquired pneumonia
  • cost
  • hospital
  • length of stay
  • levofloxacin
  • moxifloxacin
  • treatment outcomes
Regions :
  • North America
ViH Article Tags :